Another patient developed only moderate levels of reactive antibodies (3.75 BAU/mL); this patient is currently treated with the BTK inhibitor ibrutinib for chronic lymphocytic leukemia (CLL). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.